Prat et al. (2015) studied a cohort of 957 BC (10.3% HER2-enriched, 18.2% Luminal B, 30.6% Luminal A, and 32.7% Basal-like by PAM50 classification) treated with NAC, and showed that the most significant variable associated with pCR was cT-stage (p < 0.001). The gene discussed is ERBB2; the disease is breast cancer.